Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Investors may react cautiously to news that APLLTD's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 21.465357
debtToEquity 24.232000
earningsGrowth 0.148000
revenueGrowth 0.095000
grossMargins 0.722320
operatingMargins 0.121340
trailingEps 30.680000
forwardEps 43.500000

APLLTD's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
APLLTD's low Debt-to-Equity ratio demonstrates that the company is not over-leveraged. This means it maintains a healthy balance between debt and equity, lowering financial risk and contributing to overall financial stability, which could attract risk-averse investors.
APLLTD's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for APLLTD's financial growth.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

APLLTD's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in APLLTD's ability to achieve future growth.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


11 transactions to buy APLLTD shares were recorded, with market price at 835.5045443448154.The period under consideration saw no buy transactions.The increased selling at Alembic Pharmaceuticals Limited's current price levels points to potential future declines. If this selling trend persists, the stock could face more downward pressure, suggesting investor pessimism about its future performance.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts' recent buy bias toward APLLTD suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see APLLTD as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.